See more : Orient Overseas (International) Limited (OROVF) Income Statement Analysis – Financial Results
Complete financial analysis of Psyence Group Inc. (PSYGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Psyence Group Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Parks! America, Inc. (PRKA) Income Statement Analysis – Financial Results
- Acer Incorporated (2353.TW) Income Statement Analysis – Financial Results
- coconala Inc. (4176.T) Income Statement Analysis – Financial Results
- Seraphine Group PLC (BUMP.L) Income Statement Analysis – Financial Results
- NIKE, Inc. (NKE.DE) Income Statement Analysis – Financial Results
Psyence Group Inc. (PSYGF)
About Psyence Group Inc.
Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 97.93K | 92.27K | 52.64K | 24.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -97.93K | -92.27K | -52.64K | -24.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.58M | 2.30M | 115.94K | 21.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.43M | 3.32M | 4.19M | 92.51K | 19.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 152.16K | 253.62K | 146.62K | 131.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.58M | 3.58M | 4.34M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Other Expenses | 0.00 | 5.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.16M | 5.97M | 4.51M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Cost & Expenses | 5.16M | 5.97M | 4.51M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Interest Income | 3.57K | 7.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 72.63K | 123.14K | 1.39K | 1.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 92.93K | 92.27K | 52.64K | 24.50K | 206.30K | 171.86K | 161.14K | 52.52K | 22.82K |
| EBITDA | -5.17M | -5.88M | -4.46M | -3.80M | -19.06K | -45.82K | -19.97K | -54.79K | -14.69K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.16M | -6.09M | -4.59M | -92.51K | -19.06K | -45.82K | -19.97K | -54.79K | -14.69K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -64.28M | -208.35K | -145.07K | -13.45M | 0.00 | 32.50K | 4.00 | 4.00 | -46.00 |
| Income Before Tax | -69.45M | -6.08M | -4.60M | -92.51K | -19.06K | -13.32K | -19.97K | -54.79K | -14.74K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.18K | -83.90K | -8.12M | -206.29K | -171.86K | -161.14K | -52.52K | -22.82K |
| Net Income | -69.45M | -6.08M | -4.60M | -92.51K | -19.06K | -13.32K | -19.97K | -54.79K | -14.74K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.52 | -0.07 | -0.05 | 0.00 | -0.01 | -0.02 | -0.04 | -0.11 | -0.03 |
| EPS Diluted | -0.52 | -0.07 | -0.05 | 0.00 | -0.01 | -0.02 | -0.04 | -0.11 | -0.03 |
| Weighted Avg Shares Out | 133.34M | 89.01M | 85.53M | 51.21M | 1.67M | 721.50K | 497.22K | 497.22K | 497.22K |
| Weighted Avg Shares Out (Dil) | 133.34M | 89.01M | 85.53M | 51.21M | 1.67M | 721.50K | 497.22K | 497.22K | 497.22K |
Psyence Appoints Intellectual Property Expert to Its Board of Directors
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Psyence Group says its functional mushroom brand will be sold in South Africa's largest coffee retail chain
Source: https://incomestatements.info
Category: Stock Reports